Orchid Pharma turns profitable in Q2 FY27, consolidated PAT ₹28.6 Cr, revenue up 14% YoY
revenue +14.3% · margins expanding · inline vs street
₹341.27 Cr
+14.3% YoY
₹28.59 Cr
7.96%
+10.8pp YoY
₹4.77
Orchid Pharma's first full quarter since the Dhanuka Laboratories amalgamation shows a clean turnaround: consolidated PAT was ₹28.6 Cr in Q2 FY27 against a restated loss of ₹0.9 Cr in Q2 FY26, on revenue of ₹341.3 Cr, up 14.3% year-on-year and 12.2% sequentially from Q1 FY27's ₹304.2 Cr. Consolidated EPS was ₹4.77 (not annualised). Standalone — where the merged Dhanuka business itself sits — was stronger still, with PAT of ₹36.8 Cr (EPS ₹6.14) on the same ₹341.3 Cr revenue base; the ~₹8.2 Cr gap to consolidated PAT is a >20% divergence driven by loss-making US subsidiaries, worth flagging since readers will see both numbers.
Q2 FY-2027 vs prior quarters
Margins expanded on both counts: consolidated NPM rose to roughly 8.4% from -2.8% a year ago and about 1.1% last quarter, while EBITDA-level operating margin improved to around 7.1% from -0.8% YoY and 4.6% QoQ. The improvement sits mainly on the operating cost lines, which grew slower than revenue, with no exceptional item in this quarter (FY26's one-off was a ₹7.33 Cr labour-code provision booked only in the full-year column). Consolidated PAT also carries a ₹1.71 Cr profit share from associate Orbion Pharmaceuticals, versus a ₹2.39 Cr loss-share a year ago; stripping that out, core consolidated profit before associates was ₹26.9 Cr.
The stock went into the print at ₹884.4, down 6.4% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.
FY27 growth guidance withheld; management cited unpredictability. 7-ACA targeting March 2027 commercial batch; Cefiderocol facility by Dec 2026, product approval Q3 FY28. Exblifep partnerships expanding; Russia deal $178M estimated 10-year value.
Management continues to withhold formal FY27 growth guidance, citing unpredictability, so this print cannot be graded against a company-issued number. H1 FY27 revenue of ₹645.4 Cr is up 14.9% YoY, near the top of the 10-15% band the Street has been using as its working guidance, though a separate consensus FY27 growth forecast of 58.8% appears benchmarked against Orchid's pre-restatement (pre-merger) FY26 base rather than the like-for-like figures in this filing. Actual revenue of ₹341.3 Cr sits inside the ₹320-350 Cr range flagged in our pre-result preview; no public Street PAT estimate for the quarter could be found. No company press release accompanying this result was available to cross-check management's own framing of the quarter. The quarter also carried board actions flagged pre-result: the Exblifep licensing deal with Libra for Latin America (Oct 24) and a resolution for up to ₹600 Cr in fresh capital (Oct 20), alongside the Sep 24 listing of the merged entity's shares — none show up in revenue yet but mark the integration and funding track management is executing against.
W1
Whether revenue growth holds near the 14-15% run-rate seen in Q1-Q2 FY27, given management still declines to issue formal FY27 guidance.
W2
Use and progress of the up-to-₹600 Cr fundraising resolution approved Oct 20 — deleveraging vs. capex allocation.
W3
Management-stated capacity milestones: 7-ACA commercial batch targeted March 2027 and the Cefiderocol facility targeted December 2026.
Converted from ₹ Lakh; Sep'25 comparatives are merger-restated (Dhanuka amalgamation, NCLT order, effective Jul 10 2026, appointed date Apr 1 2024) to revenue ₹298.5 Cr / PAT ₹(0.9) Cr — our stored year-ago figures (₹193.5 Cr / ₹-5.7 Cr, which match Q1 FY26 pre-restatement, not Q2) predate this restatement, so YoY here uses the PDF's own restated column; no exceptional items in any quarterly column (FY26's ₹7.33 Cr labour-code provision hit only the full year); consolidated PAT includes a ₹1.71 Cr associate (Orbion) profit share.
Merger Momentum on Test: Dhanuka Integration and FY27 Growth Delivery
Orchid Pharma reports Q2 FY27 with full quarter of merged operations behind it. The Street watches execution on 10–15% FY27 guidance and the run-rate sustainability from Q1's 16% growth. Key: margins post-integration and traction on the Exblifep licensing deal.
The Setup: Merged Platform, Full Quarter Test
Orchid Pharma's Dhanuka merger became effective on July 10, 2026, reshaping the scale and portfolio. Q1 FY27 (ended June 30) delivered ₹304 Cr revenue, a 16% increase on Q1 FY26's ₹263 Cr. Now Q2 will be the first full quarter of merged operations—a critical inflection point for testing whether the enlarged franchise can sustain growth momentum and generate the margin lift promised in the rationale. The Street's 58.8% FY27 revenue growth forecast and 603.6% profit growth estimate reflect recovery expectations and operational leverage.
~₹320–350 Cr
Merged platform baseline from Q1 (₹304 Cr); guidance implies 10–15% FY27 growth
Recovery post-integration
Q1 PAT ₹119.4 Cr; consolidation gains and fixed-cost absorption on watch
₹976
3 analysts, Strong Buy; vs. current ₹859.5 (+13.6% implied upside)
58.8%
Reflects merger scale and organic traction; execution track record critical
What Strong vs. Weak Looks Like
Strong quarter: Revenue in the ₹340–360 Cr band (upper half of guidance range), PAT margin stable or expanding on cost absorption, and a confident management tone on antibiotic portfolio traction and the Exblifep licensing deal (signed with Libra in Oct 2026). Reaffirmation or tightening of FY27 guidance on the merger baseline. Weak quarter: Revenue miss <₹320 Cr suggesting slower customer transition or antibiotic category headwinds. PAT margin compression from integration drag (duplicate costs, sales overlap, inventory write-downs). Downward guidance revision or cautious commentary on liquidity ahead of the planned ₹600 Cr fundraise (resolution passed Oct 20).
On Track with Guidance?
Q1 FY27's 16% revenue growth was merger-inclusive, setting the new run-rate. Management guidance of 10–15% FY27 sales growth appears achievable if Q2 holds ~₹320 Cr+ (flat to +5% QoQ) and antibiotic and acute-care products maintain traction. The Street's outsized 58.8% FY27 estimate likely assumes pro-forma merged comparison or a stronger H2 recovery. Profitability guidance (603.6% growth estimate) is lofty but grounded in merger synergies (elimination of overlap, shared manufacturing/distribution) and operating leverage on a 50%+ larger revenue base. Watch for management's tone on timing of those synergies.
What the Street Says
Since Last Quarter: Key Filings & Events
1 · Exblifep Licensing to Libra (Oct 24)
Orchid Pharma signed a licensing and supply agreement with Laboratorio Libra S.A., granting exclusive Latin America rights to Exblifep® (cefepime/enmetazobactam), the antibiotic combination. This expands the product's footprint and signals confidence in its market potential. Monitor for revenue recognition timelines and upfront/milestone payments.
2 · ₹600 Cr Fundraising Resolution (Oct 20)
Board passed an enabling resolution to explore ₹600 Cr capital raise through equity, convertible instruments, or other mechanisms. No committed funds announced yet, but the motion signals growth capex and/or debt reduction intent. Q2 results may include management commentary on fundraising timelines.
3 · Property Acquisition & DBS Bank Lease Closure (Sep 22)
Orchid Pharma purchased a property previously leased from DBS Bank, ending the lease arrangement. A routine capex move; consolidates real-estate assets post-merger. No earnings surprise.
4 · FII Outflow Pressure (Ongoing)
FII ownership dropped from 2.69% (FY25 Q4) to 0.81% (FY27 Q1), a 188 bps decline. DII stable at 20.75%. Promoter unchanged at 69.84%. Monitor FII redemption trends post-result and any analyst downgrades.
5 · Investor Roadshow (Sep 28–30)
Whole-Time Director Mridul Dhanuka participated in Mumbai investor meetings. Routine roadshow; likely to discuss merger integration and FY27 outlook.
The Close: Three Things to Watch on Result Day
Orchid Pharma reports Q2 FY27 on November 14 with a full quarter of merged operations behind it. Expectations are set: ₹320–350 Cr revenue, margin recovery, and confirmation of 10–15% FY27 growth on track. The Street's Strong Buy consensus and ₹976 target embed confidence, but thin coverage and rising FII exits suggest limited institutional demand. Watch (1) revenue beat/miss vs. guidance band and the margin trend post-integration; (2) management commentary on antibiotic portfolio momentum, Exblifep traction, and synergy timelines; and (3) any update on the ₹600 Cr fundraise and H2 capex/debt strategy. A solid Q2 could stabilize the stock and narrow the gap to the ₹976 target; a miss risks further FII pressure and guidance cuts.
Orchid Pharma's post-merger arc hinges on Q2 execution. The enlarged franchise, anchored by Dhanuka's portfolio, enters its first full reported quarter with expectations for sustained 10–15% FY27 growth and margin recovery. Early signals—Q1's 16% revenue uptick and the Exblifep licensing deal—are encouraging, but FII selling and thin analyst coverage warrant caution. Result day will test whether the Street's 58.8% FY27 forecast and Strong Buy consensus hold water or face reality-check revisions.